IDT explains mRNA vaccine related share price rise
Comment by Peter Roberts Melbourne drug development and manufacturing company IDT Australia has again been asked by the stock exchange to explain a totally understandable surge in its share price in recent times. The background to this begins with the Australian government’s approach to market to ascertain potential sites where mRNA vaccine production could take…











